## This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

TTY. DOC	KET NO.	SERIAL	NO.	FILING DATE	6	1 PE	\	
3757-0272		09/287,3	177	April 7, 1999	. / °	AN 1 A 2000	å	
PPLICANT		0712013	,,,,	GROUP	13 V2	With A voice		
Robert J. D'	Amato		. :	1614	SAL			
obere g. B			U.S. PATI	ENT DOCUMENTS		CO TRANSCO	V7140	· · · · · · · · · · · · · · · · · · ·
XAMINER INITIAL	DOCUMENT NUMBER	DATE	·	NAME	CLASS	SUBCLASS	FIL IF APP	ING DATE ROPRIATE
AA.	2,830,991	04/15/58	Keller, et	al.	260	281	<u> </u>	<del>:</del>
	3,560,495	02/02/71	Frankus, I	Е.	260	247.1		
AC	3,563,986	02/16/71	Frankus, I	Ε.	260	247.1		
AD	3,625,946	12/07/71	Heinrich,	et al.	260	281	· ·	
AE	3,705,162	12/05/72	Graudums	s, et al.	260	281		
AF	4,552,888	11/12/85	Koppel, et	t al.	514	474		· ·
AG	4,994,443	02/19/91	Folkman,	et al.	514	56 <sup>-</sup>		· ·
AH	5,001,116	03/19/91	Folkman,	et al.	514	56	•	· 
AI	5,021,404	06/04/91	Folkman,	et al.	514	26		
V AJ	5,134,127		Stella, et a		514	058		
nd I	DOCUMENT NUMBER	DATE	COUNTRY	ATENT DOCUMEN	NAME		TRANS	LATION NO.
() AK	1,182,709	03/04/70	ЕРО			·		
AL	58-131978	08/06/83	Japan			·		X
AM	63-119500	05/24/88	Japan					Χ.
AN	0325199	07/26/89	EPO	Takeda Chemi	cal Industries	, LTD	,	
AO	0357061	03/07/90	EPO	Takeda Chemi	cal Industries	, LTD		
AP	WO 91/10424	07/25/91	PCT	Northwestern	University			
AQ	WO 92/14455	09/03/92	PCT	The Rockefelle	er University	·		
AR	WO 92/18496	10/29/92	PCT	Grünenthal GM	ИВН			X
AS	WO 94/20085	09/15/94						
V AT	WO 95/04533	02/16/95	PCT	Andrulis Phart	naceuticals C	Corporation		

ATTY. DOCKET NO. SERIAL NO. 03757-0272 09/287,377					FILING DATE April 7, 1999			
APPLIC Robert					GROUP 1614			
		Anaco	. !	U.S. PAT	TENT DOCUMENTS			
XAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
W	ВА	5,385,901	01/31/95	Kaplan,	et al. OPE	514	231.5	
V	BB	5,399,363	03/21/95	Liversid	ge, et a 77 7 1 8 2000 &	424	490	
	вс	5,405,855	04/11/95	Andrulis	ENTE CYNCELLE	71 <b>4W</b> 514	323	
	BD	5,434,170	07/18/95	Andrulis		514	323	
	BE	5,443,824	08/22/95	Piacquad	io	424	78.02	
\ <u>{</u>	BF	5,502,066	03/26/96	Heinema	nn	514	360	,
γ 	BG	5,605,684	02/25/97	Piacquad	io	424	78.02	
<u> </u>	ВН	5,605,914	02/25/97	Muller		514	339	
V.	BI	5,643,915	07/01/97	Andrulis	, Jr. et al.	514	279	
	BJ	5,654,312	08/05/97	Andrulis	, Jr. et al.	514	279	
<del>- W</del> -	BK	5,679,696	10/21/97	Fenton e	t al.	514	354	
V	BL	5,731,325		Andrulis	, Jr. et al. ding Author, Title, Date, Per	514	323	
		OTHER R	EFERENC	ES (Incine	ang Aumor, Title, Date, Ter	unem 1 a	ges, Lic.)	
M	BM				of Normal and Malignant tissuttic Transplants", J. Nat'l Can			
	BN	Allegri, A., "C 124-127 (196		inefficacia	della Talidomide Nella Terap	ia dei Tu	mori", <i>Gazzet</i>	ta Medica Italiana, <sub>I</sub>
	ВО	Tumor Progre	ession", The	FASEB J	of Nitric Oxide and the p53 Topurnal, Vol. 11, pp. 443-448	(1997)		
	BP	20, No. 3, pp.	84-86 (196	5)	he Course of Experimental Cl			
	BQ	Arch. Dermat	ol., Vol. 120	), No. 11,	ed Peripheral Neuropathy. Eff pp. 1466-1470 (1984)			
	BR	Microbiologic	a Scandinav	ica, Vol. 5	Anti-Neoplastic Effect of Th 59, pp. 491-499 (1963)			
1	BS				Chemotherapy", The Lancet			
$\forall$	BT BU				zytischer Infiltration", Der H natosus Hypertrophicus et Pro			
XAMINE	2	Tello (me.			DATE CONSIDI	ERED 1911	<u> </u>	

conformance and not considered. Include copy of this form with next communication to applicant.

			vb (Use	several sheets if necessary	PEVO	.,	
ATTY. DOCKET NO. SERIAL NO.			SERIAL NO.	FILING DATE	700 × 0000 ×	1	
03757-0	272		09/287,377	April 7, 1999	E WWW GETTED	到AO JIAM	
APPLICANT				GROUP		<del>}</del> -	
Robert ,	J. D'A	mato		1614	FIENT & TRADEMACE		
1			REFERENCES (Incl.	ding Author, Title, Date			
()/)				ctor Production in Patient	s with Leprosy", Infection	and Immunity, Vol. 60,	
1	CA		1441-1446 (1992)	and Dossible Made of Ast	ion in Reactional Lepromat	one I amount and in	
1 (1)	CB				.10n in Reactional Lepromai , No. 3, pp. 317-323 (1982)		
	CC				ties of Thalidomide: Effects		
		Polymorph (1984)	onuclear Leukocytres ar	nd Monocytes", J. Am. A.	cad. Derm., Vol. 11, No. 5,	Part 1, pp. 814-819	
	CD				licale, Vol. 12, No. 15, pp. 9		
	CE		al., "The Effects of Thal Exp. Morph., Vol. 41, p		ues on the Regenerating Fo	relimb of the Newt", J.	
	CF	Beck, Jr. et 365-374 (1	al. "Vascular Developn 997)	nent: Cellular and Molecu	lar Regulation", The FASE	• • •	
	CG	pp. 289-29	8 (1987)	•	on artrite reumatoide", Clin.		
	СН	(1983)			Sem. Hop. Paris, Vol. 59, 1		
	CI	Bensinger, W.I., "Supportive Care in Marrow Transplantation", Curr. Opin. Oncol., Vol. 4, No. 4, pp. 623 (1992)					
	Cl	Bernal, et a 8, pp. 599-		fects of Thalidomide in A	Actinic Prurigo", Int'l. J. of	Dermat., Vol. 31, No.	
	CK	Vol. 99, N	o. 11, pp. 2691-2700 (1	997)	Formation", Journal of Cl	_	
	CL				on Thalidomid und teratoge II, pp. 1640-1642 (1979)	ne Wirkung der	
	СМ		J. et al., "A Peptide Seq., Science, Vol. 2, pp. 79		and Rapid Degradation in the	ne Endoplasmic	
	CN		c, et al., "Thalidomide a , pp. 321-323 (1996)	nd Recurrent Aphthous S	tomatitis: a Follow-up Stud	y", <i>Dermatology</i> , Vol.	
	CO				The Washington Post (199		
	СР	Bowers, et 799-800 (1		ide on Orogenital Ulcerat	ion", Br. Med. Journ., Vol.	287, No. 6395, pp.	
	CQ			lite Inhibits Tumor Cell A Vol. 98, No. 4, pp. 1029-	Attachment to Concanavalin 1034 (1981)	a Coated Surfaces",	
	CR		t al., "Interstitial Chemo J. Neurosurg., Vol. 74,		er Implants for the Treatme	nt of Recurrent	
	cs	Bressler, S.	et al., "Clinicopatholog	ic Correlation of Occult C	Choroidal Neovascularizatio (1992)	n in Age-Related	
	СТ	Brodthagen, H., "Significant Response of Oral Aphthosis to Thalidomide Treatment", J. Am. Acad. Derman					
	CU	Brovarone, et al., "Occhio e gravidanza", Minerva Ginecol., Vol. 43, pp. 141-167 (1991)					
	CV	Browne, M	Browne, M.J. et al., "Expression of Recombinant Human Plasminogen and Aglycoplasminogen in HeLa Cells, Fibrinolysis, Vol. 5, pp. 257-260 (1991)				
	CW		Bubl, et al., "Dysphagia in Dermatologic Disease", Dysphagia, Vol. 8, No. 2, pp. 85-90 (1993)				
V	CX		Buckley, C. et al., "Pyoderma Gangrenosum with Severe Pharyngeal Ulceration", J. of Royal Society of Medicine, Vol. 83, pp. 590, 591 (1990)				
EXAMINE	Nun	Who La	Nea	DATE CO	NSIDERED July 29, 2000	٠	
				citation is in conformance v th next communication to	vith MPEP 609; Draw line that policant.	rough citation if not in	

LIST OF INFORMATION DISCLOSED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE	(2000
03757-0272	09/287,377	April 7, 1999	וו האות היות שותו שוובו
APPLICANT		GROUP	A. SE
Robert I. D'Amato		1614	THE TRADEMBER

Robert	J. D'Am	ato 1614					
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
	i i	Buelens, I., "Treatment of a Grade II Astrocytoma with Thalidomide (Phthalylglutamic Acid Imide)					
l M l		[Behandlung eines Astrocytoms II. Grades mit Thaliodmid (N-Phthalylglutaminsäureimid)], ArzneimForsch.,					
114	DA	Vol. 17, No. 5, pp. 646-648 (1967)					
		Bullock, W.E., "The Clinical Significance of Erythema Nodosum", Hosp. Pract., Vol. 21, No. 3, pp. 102E-					
	DB	2H, 102K-2L, 102Q-2R pas (1986)					
V		Burger, et al., "Epidermolysis Bullosa Acquisita, a Rare Late Complication of Allogeneicbone Marrow					
	DC	Transplantation?", Bone Marrow Transplant, Vol. 9, No. 2, pp. 139-141 (1992)					
	DD	Burrows, N.P., "Thalidomide Modifies Disease", Brit. Med. J., Vol. 307, No. 6909, pp. 939-940 (1993)					
	DE	Buckley, C. et al., "Pyoderma Gangrenosum with Severe Pharyngeal Ulceration", J. of the Royal Soc. of Med., Vol. 83, pp. 590-591 (1990)					
	DF	Calnan, et al., "Actinic Prurigo (Hutchinson's Summer Prurigo)", Clin. Exp. Dermatol., Vol. 2, No. 4, pp. 365-372 (1977)					
	DG	Cant, J.S., "Minor Ocular Abnormalities Associated With Thalidomide", The Lancet, p. 1134 (1966)					
	DH	Carmichael, et al., "Thalidomide: A Restricted Role", Lancet, Vol. 339, No. 8805, p. 1362 (1992)					
	DI	Cashin, C.H. et al., "Angiogenesis and Chronic Inflammation", Agents and Actions, Vol. 34, No. 3/4, pp. 332-338 (1991)					
	DJ	Casini, G. et al., "Preparazione Di Uno Degli Antipodi Ottici Della 2-Ftalimmidoglutarimmide", <i>Il Pharmaco</i> , Ed. Sc., Vol XIX, Fasc. 6, pp. 563-565 (1964)					
	DK	Chapon, et al., "Neuropathies Caused by Thalidomide", Rev. Neurol., Vol. 141, No. 11, pp. 719-728 (1985)					
		Chaudhry, A. et al., "Effects of Prednisolone and Thalidomide on Induced Submandibular Gland tumors in					
	DL	Hampsters", Canc. Res., Vol. 26, No. 9, Part 1, pp. 1884-1886 (1966)					
		Chen, T. et al., "Plasma Pharmacokinetics and Urinary Excretion of Thalidomide after Oral Dosing in Healthy					
	DM Male Volunteers", The Am. Society for Pharma. and Experi. Therapeutics, Vol. 17, No. 4, p						
	DN	Chosidow, O, et al., "Sclerodermatous Chronic Graft-Versus-Host Disease: Analysis of Sevencases", J. Am. Acad. Dermatol., Vol. 26, No. 1, pp. 49-55 (1992)					
	DO	Claydon, et al., "Gastrointestinal Emergencies in HIV Infection", Balliere's Clin Gastroennterol., Vol. 5, No. 4, pp. 887-911 (1991)					
	DP	Clemmensen, et al., "Thalidomide Neurotoxicity", Arch. Dermatol, Vol. 120, No. 3, pp. 338-341 (1984)					
	DQ	Colville-Nash, P.R. et al., "Angiogenesis and rheumatoid arthritis: Pathogenic and Therapeutic Implications", Ann. Rheum. Dis., Vol. 51, pp. 919-925 (1992)					
	DR	Congy, et al., "Plasma Zinc Levels in Elderly Patients Hospitalized in Long Stay Units. Correlations with Other Nutritional Markers, Immunological Tests and Survival", Sem. Hop. Paris, Vol. 59, No. 45, pp. 3105-3108 (1983)					
	DS	Costa, et al., "Aseptic Adenitis in a Patient with Pyoderma Gangrenosum", Ann. Dermatol., Vol. 121, No. 8, pp. 550-552 (1994) (Abstract Only)					
	DT	Crain, E. et al., "The Effect of Thalidomide on Experimental Autoimmune Myasthenia Gravis", J. of Autoimmunity, Vol. 2, pp. 197-202 (1989)					
	DU	Crawford, C.L., "Letter: Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 839, pp. 1201-1202 (1973)					
	DV	Crawford, C.L., "Treatment of Erythema Nodosum Leprosum with Thalidomide", Lancet, Vol. 2, No. 828, pp 567-568 (1973)					
	DW	Crawford, C.L., "Use of Thalidomide in Leprosy [letter; comment]", BMJ, Vol. 302, No. 6729, pp. 1603-					
<u> </u>		1604 (1991)					
EXAMINE	ER { }.	DATE CONSIDERED					

## LIST OF INFORMATION DISCLOSED BY APPLICANT (Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE	JAM 1 B 2000 E A SECOND
03757-0272	09/287,377	April 7, 1999_	
APPLICANT		GROUP	TRADEMINET

lobert J. D'Am	ato 1614
	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
0//	Crum, et al., "A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin
III EA	Fragment", Science, Vol. 230, pp. 1375-1378 (1985)
EB	Current Bibliographics in Medicine, "Thalidomide: Potential Benefits and Risks", National Inst. Health,
	National Library of Medicine, pp. 1-72 (Jan. 1963—July 1997)
V EC	Dark, et al., "Combretastin A-4, an Agent that Displays Potent and Selective Toxicity Toward Tumor
	Vasculature", Cancer Research, Vol. 37, pp. 1829-1834 (1997)
ED	David-Bajar, K.M., "Subacute Cutaneous Lupus Erythematosus", J. Invest. Dermatol. Vol. 100, No. 1, pp. 2s-8s (1993)
EE	D'Amato, R. J. et al., "Thalidomide is an Inhibitor of Angiogenesis", <i>Proc. Natl. Acad. Sci.</i> , Vol. 91, pp. 4082-4085 (1994)
EF	D'Amato, et al., "Angiogenesis Inhibition in Age-Related Macular Degeneration", Opthalmology, Vol. 102 No. 9, pp. 1261-1262 (1995)
EG	D'Amato, et al., "Microscopic Analysis of Retinal-Vessels Utilizing Fluorescein-Labeled High-Molecular-Weight Dextrans", <i>Invest. Opthamol. &amp; Visual Science</i> , Vol. 33, No. 4, p. 1082 (1992)
EH	De, A.U. et al., "Possible Antineoplastic Agents I", J. of Pharma. Sci., Vol. 64, No. 2, pp. 262-266 (1975)
EI	De Cock, K., "Treatment of Ulcerative Colitis", Brit. Med. J., Vol. 1, pp. 1356 (1979)
EJ	DeKlerk, et al., "New Methods of Treatment for Renal Allotransplants Using the Baboon as a Primate Experimental Model", J. Urol. Vol. 102, No. 5, pp. 532-540 (1969)
EK	Dhodapkar, et al., "A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients with Multiple Myeloma", UARK 98-003, pp. 1-15, 1945
EL	Dicken, C. H., "Malignant pyoderma", J. of the Am. Acad. of Dermatol., Vol. 13, No. 6, pp. 1021-1025 (1985)
EM	DiPaolo, et al., "Thalidomide: Effects on Ehrlich Ascites Tumor Cells in vitro", Science, Vol. 144, pp. 1583 (1964)
EN	DiPaolo, "Effect of Thalidomide on a Variety of Transplantable Tumors", Cancer Chemo. Reports, Vol. 29, pp. 99-102 (1963)
EO	DiPaolo, "In Vitro Test Systems for Cancer Chemotheraphy. II. Correlation of In Vitro Inhibition of Dehydrogenase and Growth with In Vivo Inhibition of Ehrlich Ascites Tumor", P.S.E.B.M., Vol. 114, pp. 384-387 (1963)
EP	DiPaolo et al., "Teratogenesis-oncogenesis: A Study of Possible Relationships", Arch. Path., Vol. 81, pp. 3-23 (1966)
EQ	Dorveaux, et al., "Le Traitement Actuell du Lupus Erythemateux Chronique", Le Concours Med. Vol. 106, No. 31, pp. 2957-2961 (1984)
ER	Doutre, et al., "Pyoderma Gangrenosum and Hemopathies. A propos of 2 Cases", Nouv Rev Fr Hematol, Vol. 29, No. 4, pp. 251-254 (1987)
ES	Dunn, et al., "Bone Marrow Transplantation and Cataract Development", Arch. Ophthalmol. Vol. 111, No. 10, pp. 1367-1373 (1993)
ET	(Editorial) "Thalidomide in Dermatology and Leprosy", Lancet, Vol. 2, No. 8446, pp. 80-81 (1985)
EU	(Editorial) "Thalidomide Tested for Treatment of AIDS", U.S. Pharm., Vol. 18, No. 8, p. 14 (1993)
EV	Eger, K. et al., "Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide", Arzheim. Forsch/Drug Res., Vol. 40 (II), No. 10, pp. 1073-1075 (1990)
EW	Ehrlich, G.E., "Behcet's Disease: Current Concepts", Comprehensive Therapy, Vol. 15, No. 1, pp. 27-30 (1989)
EX	Elia, et al., "Giant Esophageal Ulcer Treated with Steroids in AIDS Patient(2)", J. Acquired Immune Defic. Syndr., Vol. 5, No. 8, pp. 848-849 (1992)
AMINER\	DATE CONSIDERED

						<b>\</b> 0 ,	` %\				
						JAN 1 9	2000 🛞	4			
FORM	PTO-14	49, A	dapted			E	- \$\frac{3}{8}\frac{1}{2}			PF	6 of 17
						4 /HAL	MEDISCLO		ABPI	LICANT	<u> </u>
	Y. D 57-02		KET N	IO.	SERIA 09/287	L NO.	FILING DA April 7, 19		CO THAN	1 8 2000	
APP	LICA	NT					GROUP		1		Lou Hong
Kob	ert J.	. D'	Amato		DEFEDEN	JCFS (Inclu	1614 ding Author, Title	la Data Par	Trin on B.	A X R A R X A	1000
1							hous Stomatitis o				reatment with
		FA		Thalidomide	e", Oral Sur	gery, Oral M	ledicine, Oral Pa	thology, Vol	. 64, No. 3	3, pp. 289-29	92 (1987)
		FB									8005, p. 251 (1977)
$  \setminus  $		FC					", Transplant Pro				ment Schedule that (1992)
4		FD			O. et al., "	Synthesis and					alimides", Acta Pharm.
		FE		Fabro, S. et	al., "The M	etabolism of	Thalidomide: So ol. 25, pp. 352-36		al Effects	of Thalidon	nide and its
		FF		992 (1964)							Sci., Vol. 3, pp. 987-
		FG		Teratogenes	is, Chapter	5, pp. 159-17	78 (1981)				Basis of Chemical
		FH		pp. 539-544	(1992)				_		nol., Vol. 140, No. 3,
		FI		Faure, et al. No. 10, pp.			motaxis: Inhibit	ion by Thali	domide",	Pathol. Biol	l. (Paris), Vol. 29,
		FJ		Faure, et al. No. 3, pp. 2			ukocytes Chemo	taxis by Tha	lidomide"	, Arch. Deri	matol. Res., Vol. 269,
$\prod$		FK					TNF-α on Intrace tages", <i>FEMS Mi</i>				uerin) Growth in 5, pp. 337-346 (1992)
		FL		Fickentsche	r, K. et al., '		cal Properties and				trahydrophthalimides",
		FM					omide on Splenor 211, No. 5055, p			n) in the Chi	ick Embryo. Treatment
		FN					othetical Relation ng (Germany We				oryopathy and Collagen 1981)
		FO		Folkman, J.	et al., "An	giogenesis",	J. Biol. Chem., \	Vol. 267, No	o. 16, pp.	10931-1093	4 (1992)
		FP					nibition and Tum ne", Science, Vo				or a Heparin
		FQ		Folkman, J. Vol. 339, pr			giogenesis During	g the Transit	ion from H	Hyperplasia	to Neoplasia", Nature,
		FR		Folkman, J.	et al., "Tun	nor Behavior	in Isolated Perfu ne Intestinal Seg				Metastases of Biopsy 502 (1966)
		FS		Folkman, J.,	"Tumor A		Therapeutic Imp				
		FT		Folkman, J., Company, p	"Angioger	nesis and Its	Inhibitors", Impo	ortant Advan	ces in One	cology, J.B.	Lippincott H.
	_	FU			"Angiogen	esis in Cance	er, Vascular, Rhe	umatoid and	Other Dis	sease", <i>Natu</i>	re Medicine, Vol. 1,
		FV			"What is th		hat Tumors are A	Angiogenesis	Depender	nt?", <i>J. Naai</i>	t' Cancer Inst., Vol. 82
		FW		Francois, J.,	"Embryolo		nt Epithelial Dys				72, pp. 417-433 (1976)
		FX		pp. 369-370	(1991)		Property Land	1000			atol., Vol. 29, No. 8,
$\vdash \downarrow$	1/-	FY	7 4	pp. 542-547	(1990)			<u> </u>			Circulating Blood of
		FZ		Healthy Ma	les", Lepr.		6, No. 1, pp. 35-	39 (1985)	- 0		
	MINER			Ne An		other or mot -		ATE CONSID			rough citation if not in
							h next communica			Diaw mile th	nough chanon if not in

JÁN 1 9 2000

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE	DETTE NAL CETTED
03757-0272	09/287,377	April 7, 1999	INAIL BATE CANAL
APPLICANT		GROUP	ENTE TRADE
Robert J. D'Amato		1614	
OTHE	P PEFFRENCES (Incl	uding Author Title Da	to Partinant Pages Ftc \

TODCI C	J. 10 71	
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
$\mathcal{M}$	GA	Gaetani, M., "Studi Sull'Attivita Antitumorale Della Talidomide", Giornale Italiano diu Chemioterapia, pp. 83-86, 1994
1	GB	Gehanno, et al., "Mouth and Pharyngeal Hyperalgesic Syndromes in AIDS", Ann. Otolarygol Chir. Cervicofac, Vol. 107, No. 5, pp. 311-313 (1990)
V	GC	Genvo, et al., "Treatment of Aphthosis with Thalidomide and with Colchicine", <i>Dermatologica</i> , Vol. 168, No. 4, pp. 182-188 (1984)
	GD	Geoghiou, et al., "HIV-Associated Oesophageal Ulcers Treated with Thalidomide", Med. J. of Australia, Vol. 152, pp. 382-383 (1990)
	GE	Gershbein, "Effect of Transplanted Tumor and Various Agents on Liver Regeneration During Pregnancy", P.S.E.B.M., Vol. 126, pp. 88-92 (1967)
	GF	Gershbein, L. L., "The Thalidomide Analog, EM 12, Enhances 1,2-dimethylhydrazine-induction of Rat Color Adenocarcinomas", Canc. Ltrs, Vol. 60, pp. 129-133 (1991)
	GG	Gershbein, L. L., "Effect of Various Agents on Liver Regeneration and Walker Tumor Growth in Partially Hepatectomized Rats", Canc. Res., Vol. 26, No. 9, pp. 1905-1908 (1966)
	GH	Ghigliotti, G. et al., "Thalidomide: Treatment of Choice for Aphthous Ulcers in Patients Seropositive for Human Immunodeficiency Virus", J. of the Am. Acad. of Dermatol., Vol. 28, No. 2, Part I, pp. 271-272 (1993)
	GI	Gimbrone, M.A. et al., "Tumor Dormancy in Vivo by Prevention of Neovasularization", <i>Journal of Experimental Medicine</i> , Vol. 136, pp. 261-276 (1972)
	GK	Gimbrone, M. A. et al., "Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea", J. Nat. Canc. Instit., Vol. 52, No. 2, pp. 413-419 (1974)
	GL	Goihman-Yahr, Mauricio et al., "Significance of Neutrophil Activation in Reactional Lepromatous Leprosy: Effects of Thalidomide in vivo and in vitro. Activation in Adjuvant Disease", <i>Int. Archs. Allergy Appl. Immun.</i> , Vol. 57, pp. 317-332 (1978)
	GM	Goihman-Yahr, M., et al., "Autoimmune Diseases and Thalidomide II. Adjuvant Disease, Experimental Allergic Encephalomyelitis and Experimental Allergic Neuritis of the Rat", <i>Int. J. Leprosy</i> , Vol. 42, No. 3, pp. 266-275 (1974)
	GN	Gorin, I., et al., "Thalidomide May Cure AIDS Ulcers", Nurs. Times, Vol. 86, No. 24, p. 10 (1990)
	GO	Gorin, I., et al., "Thalidomide in Hyperalgic Pharyngeal Ulceration of AIDS", <i>Lancet</i> , Vol. 335, p. 1343 (1990)
	GP	Goulden, V., et al., "Linear Prurigo Simulating Dermatitis Artefacta in Dominant Dystrophicepidermolysis Bullosa", Br. J. Dermatol., Vol. 129, No. 4, pp. 443-446 (1993)
	GQ	Grabstald, H. et al., "Clinical Experiences with Thalidomide in Patients with Cancer", Clinical Pharmacol. an Therapeutics, Vol. 6, pp. 298-302 (1965)
	GR	Grant, D.S. et al., "Scatter Factor Induces Blood Vessel Formation in vivo", <i>Proc. Natl. Acad. Sci.</i> , Vol. 90, pp. 1937-1941 (1993)
1//	GS	Grinspan, et al., "Treatment of Aphthae with Thalidomide", J. Am. Acad. Dermatol., Vol. 20, No. 6, pp. 1060-1063 (1989)
A	GT ^	Grinspan, D., "Significant Response of Oral Aphthosis to Thalidomide Treatment", Am. Acad. of Dermutol., Vol. 12, No. 1, Part 1, pp. 85-90 (1985)
EXAMINE	R	DATE CONSIDERED

		(Use seve	eral sheets if necessary)				
ATTY. DOC	KET NO.	SERIAL NO.	FILING DATE				
03757-0272		09/287,377	April 7, 1999				
APPLICANT	•	07/207,377	GROUP				
D.L4 T D!	A		1614				
Robert J. D'		REFERENCES (Inclusion	ding Author, Title, Date, Pertinent Pages, Etc.)				
(V)	Grosshans, I	E., et al., "Thalidomide I	Therapy for Inflammatory Dermatoses", Int. J. Dermatol, Vol. 23, No. 9,				
\ /\  HA	pp. 598-602		ione Immunodepressiva Della Talidomide e del Prednisolone in Ratti				
$(      _{HB}  $			nente Indotte", Cancro, Vol. 22, pp. 503-512 (1969)				
нс			n Immunodeficiency Virus (HIV) Patients. A Review of Safety No. 2, pp. 116-134 (1992)				
HD	Günzler, V.,	"Thalidomide—A Thera	apy for the Immunological Consequences of HIV Infection?", Medical				
HE		Vol. 30, No. 2, pp. 105	in-109 (1989)  It is the transfer of Refractory Rheumatoid Arthritis—The Thalidomide Experience",				
	The J. of Rh	neumatology, Vol. 16, N	(o. 2, pp. 158-163 (1989)				
HF	and Rheumo	atism, Vol. 27, No. 10, p	idomide A Promising New Treatment for Rheumatoid Arthritis", Arthritis pp. 1118-1121 (1984)				
HG		E. M.D., "Studies Involvaw Journal, Vol. 48, pp.	ing Orphan Products for Treating/Diagnosing Women's Diseases", Food 205-211 (1992)				
НН	Hamza, M. I	M.D., "Behcet's Disease	, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", <i>ology</i> , Vol. 8, No. 4, p. 427 (1990)				
НІ			's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3,				
		pp. 365-371 (1986)					
НЈ		Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", <i>Pediatric Dermatol.</i> , Vol. 10, No. 3, pp. 256-258, (1993)					
НК		Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", <i>Brit. J. of Dermatol.</i> , Vol. 127, Supp. 40, pp. 67-68 (1992)					
HL		Patient Infected with Hu	aption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to manimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152,				
HM	Harris, A., "	Antiangiogenesis for Ca	ncer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997)				
HN		F., "Chronic Cutaneous L atol, Vol. 19, No. 10, pp	Lupus Erythematosus. Thalidomide Treatment of 11 Patients", p. 812-815 (1983)				
НО	Hasper, M.F		n the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol,				
НР	Hastings, R. Selected Lat	C., et al., "Thalidomide	in the Treatment of Erythema Nodosum Leprosum. With a Note on n Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11,				
HQ	Hatfill, S.J.	et al., "Induction of Mor	phological Differentiation in the Human Leukemic Cell Line K562 by				
HR	Hayashi, S.	Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991)  Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J.					
HS	Heaton, et a	Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997)  Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85,					
НТ	Hellman, K.		Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2,				
\// HU	pp. 687-689		Seratological Investigation of Compounds Structurally and				
		Helm, FCh. et al., "Comparative Teratological Investigation of Compounds Structurally and Pharmacologically Related to Thalidomide", <i>ArzneimForsch./Drug Res.</i> , Vol. 31 (I), No. 6, pp. 941-949 (1981)					
EXAMINER	the remlyes	1 Thranks Jon	DATE CONSIDERED 29, 2000				
	Initial if reference cor	nsidered, whether or not ci	tation is in conformance with MPEP 609; Draw line through citation if not in				

JAN 1 9 2000 89

DODLE BES	1440 -	dantad	_ <del>\</del>	5.000 5017	
FORM PTO-	-1449, Ā	LIST OF	FINFORMATION	N DISCLOSED BY APPLICANT	
ATTY.	DOC	KET NO.	SERIAL NO.	FILING DATE	
03757-0272 09/287,377				April 7, 1999	
APPLIC	CANT	-	07.20.,0	GROUP	
Robert				1614	
	<del>0 ·</del>		REFERENCES (Inclu	ding Author, Title, Date, Pertinent Pages, Etc.)	
	1			for Autoimmune Disease", Medical Hypotheses, Vol. 10, pp. 437-443	
14	IA	(1983)	o. ot al., Thandoningo	Tratominano Discuso , menicai risponieses, von 10, pp. 457 445	
<del>                                      </del>	IB		S "Immune Modulator	s Thalidomide", The Oxygen Breakthrough, pp. 217-219, 1994	
<del>  \  \  -</del>	110			tment for Chronic Graft-Versus-Host Disease", Brit. J. of Haematol.	
l W	IC		23-27 (1991)	differential Citate voisus flost Discuse, Ditt. J. of Hachailot.	
<del>                                     </del>	1			ne Treatment of Graft-versus-Host Disease", Biomed. Pharmacother,	
}	ID		. 4, pp. 199-204 (1990)		
	110			Chronic Graft-versus-Host Disease in Children", Lancet, Vol. 2,	
l	ΙE		. 1317 (1988)	Chiome Grant-versus-riost Disease in Children , Lancer, Vol. 2,	
<del>                                     </del>	IF			Int. J. Dermatol., Vol. 31, No. 5, pp. 372-373 (1992)	
┝┷┼┷	IF			upus Erythematosus Treated with Thalidomide", Arch. Dermatol.,	
}	IG		o. 12, pp. 1548-1550 (1		
<del></del>	10			d Tumor Growth by Immunoneutralizing Monoclonal Antibody against	
	IH			ctor", Canc. Res., Vol. 51, pp. 6180-6184 (1991)	
	П			sis in Rats by IL-1 Receptor Antagonist and Selected Cytokine	
<del>                                     </del>	+		, Inflammation, Vol. 18		
	n			unction of Proteolytically Cleaved VEGF-2 for Vascular Endothelial and	
$\vdash$	777			B Journal, Vol. 11, pp. 498-504 (1997)	
	IK			ues of Fumagillin that Inhibit Angiogenesis and Suppress Tumor Growth",	
<b></b>	<del> </del>		, Vol. 348, pp. 555-557		
	L			Developments", AIDS Patient Care, Vol. 6, No. 6, p. 288 (1992)	
				n the News, but in more Favorable Circumstances", JAMA,	
	77		o. 11, pp. 1467-1468 (1		
j	IM			the Treatment of Oral Aphthous Ulcers in Patients with Human	
.			ciency virus infection	, The New England Journal of Medicine, Vol. 336, No. 21, pp. 1487-1493	
<del>                                     </del>	TAT	(1997)	-1 ((T) - D'	1 T	
	IN		ai., The Diagnosis and	d Treatment of Leprosy", South Med J., Vol. 69, No. 8, pp. 979-985	
	10	(1976)	"Ol' ·' · · 1 Ol · · · · · · · ·' · · · ·	'. d. T	
	Ю			in the Treatment of Leprosy Reaction with Cyclic Imides", Int. J. Lepr.	
	770		bact Dis., Vol. 39, No.		
	ΙP			mphatic Vessels in VEGF-C Transgenic Mice", Science, Vol. 276, pp.	
		1423-1426		<del></del>	
1 1	IQ			enital Ulcers, and Risk of Teratogenicity", The Lancet, Vol. 1,	
	<del> </del>		3, p. 511 (1985)		
1 1	IR			ere Orogenital Ulceration", The Lancet, Vol. 2, No. 8417-18,	
		pp. 1424-14			
1	IS			ycin D on the Production of Acute Phase Protein in the Rabbit",	
<u> </u>			Vol. 25, pp. 305-306 (1		
	IT			na Nodosum Leprosum", <i>DICP</i> , Vol. 24, No. 5, pp. 482-483 (1990)	
				ent of Prurigo Nodularis", Ugeskr Laeger, Vol. 155, No. 38,	
	IU		30 (1993) (Abstract Onl		
1 1				nd Teratogenic Propeties IV. An Outline of a Chemical Hypothesis for the	
$oxed{oxed}$	IV			', Acia Pharm. Succica, Vol. 9, pp. 543-562 (1972)	
				nd Teratogenic Properties I. Synthesis and Teratogenic Activity in Rabbits	
	IW of some Derivatives of Phthalidmide, Isoindoine-1-one, 1.2-Benzisothiazoline-3-one-1, 1-Dioxide and 4(3II)-				
	↓			ca, Vol. 9, pp. 431-436 (1972)	
M/Z	ĪΧ			d Teratogenic Properties III a Review of Available Data on Structure-	
I \	1			sm of Action of Thalidomide Analogues", Acia Pharm. Succia, Vol. 9, pp.	
<u> </u>		521f542 (19	972)		
EXAMINE	ER.	Muranha Cloner		DATE CONSIDERED 9, 2006	
EVAMIN	ED.	I de al Control		isotion is in a formation with MDDD (00). Drown line through size in it and in	

	(Use several difference of necessary)						
ATTY. DO	CKET NO.	SERIAL NO.	FILING DATE				
03757-0272	)	09/287,377	April 7, 1999				
APPLICAN		07/207,577	GROUP				
			464				
Robert J. I		DEFEDENCES (Inclu	ding Author, Title, Date, Pertinent Pages, Etc.)				
() / JA			in Behcet's Syndrome and Pustular Vasculitis", Arch. Intern. Med.,				
	Vol. 146, N	o. 5, pp. 878-881 (1986)					
JB	Biologie, V	ol. 23, pp. 246-249 (196	r-Frénateur du Talidomide vis-á-vis de deux Tumerus Greffées", Société de 3)				
∫ ]C			ease", N. Engl. J. Med., Vol. 325, No. 5, pp. 357-358 (1991)				
JD	9, pp. 685-6	90 (1994)	of HIV1: Biology and Therapy", Res. in Immunology, Vol. 145, No. 8-				
JE			ssue Culture. 3. Effects of the Second Treatments on DAB-Induced Rats in Culture", <i>Jpn. J. Exp. Med.</i> , Vol. 35, No. 4, pp. 231-248 (1965)				
JF	Keenan, R.J	. et al., "Immunosuppres	ssive Properties of Thalidomide", Transplantation, Vol. 52, No. 5, pp.				
JG	Kenyon, et a	al., "The Discovery of No	ew Inhibitors of Angiogenesis Using an Improved Mouse Corneal -367, p. S94 (Abstract only) 1996				
JH	Kim, K. J. e	t al., "Inhibition of Vasc	ular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumor 362, pp. 841-844 (1993)				
Л	Kitamoto, Y	. et al., "Vascular Endot	helial Growth Factor is an Essential Molecule for Mouse Kidney and Nephrogenesis", J. Clin Invest., Vol. 99, No. 10, pp. 2351-2357				
11	Klug, S. et a		s of Thalidomide Derivatives in the Non-Human Primate Callithrix p. 203-205 (1994)				
JK	Knighton, D Vol. 35, pp.	Jacchus", Arch. Toxicol. Vol. 68, pp. 203-205 (1994)  Knighton, D. et al., "Avascular and Vascular Phases of Tumor Growth in the Chick Embryo", Br. J. Canc., Vol. 35, pp. 347-356 (1977)					
ЛL	Dermatol, \	Knop, et al., "Thalidomide in the Treatment of Sixty Cases of Chronic Discoid Lupus Erythematosus", Br. J. Dermatol, Vol. 108, No. 4, pp. 461-466 (1983)					
JM	Chemistry,	Vol. 22, pp. 166-242 (19					
JN	pp. 427-429	Korn, et al., "The Second International Workshop on Scleroderma Research", <i>Matrix</i> , Vol. 13, No. 5, pp. 427-429 (1993)					
JO		Kroger, et al., "Synergistic Effects of Thalidomide and Poly (ADP-ribose) Polymerase Inhibition on Type II Collagen-Induced Arthritis in Mice", <i>Inflammation</i> , Vol. 20, No. 2, pp. 203-215 (1996)					
JP	Kundu, et a	Kundu, et al., "Prurigo Nodularis in an HIV Positive Man (2)", Genitourinary Medicine, Vol. 71, No. 2, pp. 129-130 (1995)					
JQ	Kürkcüoglu of Dermato	Kürkcüoglu, N. et al., "Thalidomide in the treatment of Recurrent Necrotic Mucocutaneous Aphthae", Brit. J. of Dermatol., Vol. 112, No. 5, pp. 632 (1985)					
JP		Lane, et al., "Treatment of Actinic Prurigo with Intermittent Short-Course Topical 0.05% Clobetasol 17-Propionate. A Preliminary Report", Arch. Dermatol, Vol. 126, No. 9, pp. 1211-1213 (1990)					
JS		Languillon, J., "The Effects of Thalidomide on Leprosy Reaction", Int. J. Lepr. Other Mycobact. Dis., Vol. 39, No. 2, pp. 590-592 (1971)					
JT	Larsson, H.,	Larsson, H., "Treatment of Severe Colitis in Behcet's Syndrome with Thalidomide (CG-217)", J. of Intern. Med., Vol. 228, pp. 405-407 (1990)					
ıπ	Ledo, E., "F J. Dermatol	Photodermatosis. Part I: ., Vol. 32, No. 6, pp. 38	Photobiology, Photoimmunology, and Idiopathicphotodermatoses", <i>Int.</i> 7-396 (1993)				
V	Lehner, T.,	et al., "Thalidomide, Ord	ogenital Ulcers, and the Risk of Teratogenesis", The Lancet, Vol. 8423,				
EXAMINER UTIN	he Amer		DATE CONSIDERED				
EXAMINER conformance a	Initial if reference co		tation is in conformance with MPEP 609; Draw line through citation if not in h next communication to applicant.				

JAN 1 9 2000 %

	(Use several sheets if necessary)								
ATTY.	DOC	KET NO.	SERIAL NO.	FILING DATE					
03757-	0272		09/287,377	April 7, 1999					
APPLI	CANT	, ,,		GROUP					
Robert	J. D'	Amato		1614					
	_	OTHER	REFERENCES (Inclu	ding Author, Title, Date, Pertinent Pages, Etc.)					
OLA	KA		Action of Thalidomide of pp. 127-139 (1967)	n the Induction of Tentacles in Regenerating Hydra Littoralis",					
(1)	КВ	Levy, et al., pp. 324-325	"Treatment of Erythem	a Nodosum Leprosum with Thalidomide", The Lancet, Vol. 2, No. 824,					
Y	кс	Lien, W. M.	et al., "The Blood Supp Tumor Vessels of the L	oly of Experimental Liver Metastases. II. A microcirculatory Study of the liver with the Use of Perfused Silicone Rubber", Surgery, Vol. 68, No. 2,					
	KD	Lo, et al., "T (1989)	reatment of Discoid Lu	ipus Erythematosus", Int. J. Dermatol., Vol. 28, No. 8, pp. 497-507					
	KE	Londono, F. pp. 326-328	(1973)	reatment of Actinic Prurigo", Int. J. Dermatol., Vol. 12, No. 5,					
	KF	Lovell, et al.	., "Thalidomide in Actin	nic Prurigo", Br. J. Dermatol, Vol. 108, No. 4, pp. 467-471 (1983)					
	KG	11, No. 3, p	p. 251-252 (1993)	erapy for Intestinal Chronic GVHD", Bone Marrow Transplantation, Vol.					
	КН	thalidomide'	', Annales de Medecine	hez un patient ayant une maladie de Behcet et traite au long cours par Interne, Vol. 143, pp. 479-480 (1992)					
	кі	Lymphocytic Vol. 123, pp	Lueprasitsakul, W. et al., "Effect of Thalidomide on the Incidence of Iodine-Induced and Spontaneous Lymphocytic Thyroiditis and Spontaneous Diabetes Mellitus in the BB/Wor Rat", <i>Acta Endocrino Logica</i> ", Vol. 123, pp. 79-83 (1990)						
	KJ	Lüers, H., "I 1332 (1962)	Failure of Mutagenic Ac	ction of Thalidomide in Drosophila", The Lancet, Vol. II, No. 7258, p.					
	KK		cia, M., "Antimalarials	for Children", J. Am. Acad. Dermatol, Vol. 30, No. 3, p. 510 (1994)					
	KL	Peptides", Se	cience, Vol. 2, pp. 77-7	Angiogenesis by Recombinant Human Platelet Factor-4 and Related 8 (1990)					
	KM	Makonkawk	eyoon, S. et al., "Thalid Acad. Sci., Vol. 90, pp.	omide Inhibits the Replication of Human Immunodeficiency virus type 1",					
	KN	Marin-Padill Dasypus No	Marin-Padilla, M. et al. "Thalidomide Induced alterations in the Blastocyst and Placenta of the Armadillo, Dasypus Novemcinctus Mexicanus, Including a Choriocarcinoma", <i>The Am. J. of Pathol.</i> , Vol. 43, No. 6, pp. 999-1016 (1963)						
	КО		Mascaro, et al., "Thalidomide in the Treatment of Recurrent, Necrotic, and Giant Mucocutaneous Aphthae and Aphthosis", Arch. Dermt., Vol. 115, pp. 636-637 (1979)						
	KP	Vol. 79, pp.	Matsubara, et al., "Inhibition of Human Endothelial Cell Proliferation by Gold Compounds", J. Clin. Invest., Vol. 79, pp. 1440-1446 (1987)						
	KQ		Matsuyama, T. et al., "Cytokines and HIV Infection: is AIDS a Tumor Necrosis Factor Disease?", AIDS, Vol. 5, No. 12, pp. 1405-1417 (1991)						
	KR			em Doentes Cancerosos Avançados com Tratamento Pela Talidomida elistas Medicina e Cirurgia, pp. 15-39 (1963)					
11/	KS	Maurice, et a	al., "The Effect of Thalic	domide on Arachidonic Acid Metabolism in Human Polymorphonuclear ermatol., Vol. 115, No. 6, pp. 677-680 (1986)					
	KT	McCarthy, e	t al., "Thalidomide for t	he Therapy of Graft-versus-Host Disease Following Allogeneic Bone Pharmacother, Vol. 43, No. 9, pp. 693-697 (1989)					
EXAMIN	LUTON			DATE CONSIDERED Leumber 29, LOW					
EXAMII	VER!	Initial if reference cor	sidered, whether or not c	itation is in conformance with MPEP 609; Draw line through citation if not in					
				th next communication to applicant.					

JAN 1 9 2000 FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

		(Use ser	veral sheets if necessary)				
ATTY. DOCKE	T NO.	SERIAL NO.	FILING DATE				
02757 0272		09/287,377	April 7 1000				
03757-0272 APPLICANT		09/20/,3//	April 7, 1999 GROUP				
ATTLICANT			GROUI				
Robert J. D'An			1614				
			iding Author, Title, Date, Pertinent Pages, Etc.)				
N/A   LA	McKenna, e		se, Oral Ulceration and Crohn's Disease", Br. J. Dermatol, Vol. 127,				
<b>V</b>			trointestinal Complications of AIDS", Drug Therapy, Vol. 23, No. 11, pp.				
(\ \ LB	74-83 (1993	)	•				
			ner Thalidomid-Induzierten Fehlbildung mit Einem Malignen Lymphom				
V LC			chr. Kinderheilkd., Vol. 128, pp. 27-29 (1980)				
$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $			Erythema Nodosum Leprosum with Cyclosporine A Produces Clinical Int. J. Lepr. Other Mycobact. Dis., Vol. 55, No. 3, pp. 441-449 (1987)				
LE			ngerhans Cell Histiocytosis with Thalidomide Treatment", Clinical and				
	Experiment	al Dermatol., Vol. 18, 1	No. 5, p. 487 (1993)				
LF			et of Thalidomide on Methylcholanthrene Oncogenesis in Mice",				
		a, Vol. 26, Fasc. 3, pp.	m of Action of Thalidomide on Rheumatoid Arthritis", Arthritis and				
		ol. 28, No. 7, p. 836 (1					
LH			nide on the Generation of Oxygen Intermediates by Zymosan-Stimulated				
			cytes", Arch. Dermatol. Res., Vol. 274, Nos. 3-4, pp. 363-367 (1982)				
			nalidomide and Relative Substances on the Growth of HeLa Cells",				
LJ		m. Bull., Vol. 16, pp. 2	fect on T Cell Subsets as a Possible Mechanism of Action", <i>Int. J. Lepr.</i>				
		bact. Dis., Vol. 53, No					
LK	Montrucchie	o, et al., "Tumor Necros	is Factor α-Induced Angiogenesis Depends on In Situ Platelet-Activating				
			Vol. 180, pp. 377-382 (1994)				
		. 8, pp. 611-614 (1983)	r-Kanof Disease with Thalidomide", Ann. Dermatol Venereol,				
LM			t Lymphocytes in Leprosy. II. Effect of Chemotherapy on T-Lymphocyte				
	Subpopulati	ions", J. Clin. Immuno	<i>l.</i> , Vol. 2, No. 2, pp. 69-74 (1982)				
LN			'umor", Antimicrobial Agents and Chemotherapy, pp. 531-538 (1965)				
			for Cytoxicity in Neuroblastoma Cells-I. Dependence of Growth Inhibition				
LO			logy Letters, Vol. 18, pp. 201-209 (1983) sum Associated with Behcet's Syndrome-Response to Thalidomide",				
LP			6, pp. 408-410 (1988)				
	Muthukkaruppan, Vr. et al., "Angiogenesis in the Mouse Cornea", Science, Vol. 205, No. 28, pp.1416-1418						
LQ	(1979)						
	Naafs, B. et al., "Thalidomide Therapy An Open Trial", Intl. J. of Dermatol., Vol. 24, No. 2, pp. 131-134						
LR	(1985)	Panakak Warkahan an l	annosy Pasagrah, Transment of Pagetions and Narya Damaga				
LS		Naafs, B., "Bangkok Workshop on Leprosy Research. Treatment of Reactions and Nerve Damage. Int. J. Lepr. Other Mycobact. Dis., Vol. 64, No. 4, Suppl. S21-28 (1996)					
	Neubert, "Teratogenicity: Any Relationship to Carcinogenicity?", Institute for Toxicology and						
LT		Embryopharmacology, Free University of Berlin, Berlin, Federal Rep. Of Germany, pp. 169-178, 192					
		Nguyen, M. et al., "Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients", J. of the Natl. Canc. Inst., Vol. 85, No. 3, pp. 241-242 (1993)					
LU	Nguyen M	et al "Flevated Levels	of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of				
l \ ,   LV			Cancers", J. of the Natl. Canc. Inst., Vol. 86, No. 5, pp. 356-361 (1994)				
TV I	Nicolas, J.,	et al., "Interferon Alfa T	herapy in Severe Unresponsive Subacute Cutaneous Lupus				
LW	Erythemato	sus", New Engl. J. Meg	., Vol. 321, No. 22, pp. 1550-1551 (1989)				
EXAMINER (	Jen 29	2000 knowned	Mej Member 29 2000				
EXAMINER: Init	tial if referen		tation is in conformance with MPEP 609; Draw line through citation if not in				
conformance and no	ot considered. Inc	lude copy of this form wi	th next communication to applicant.				

 $\hat{\mathbf{r}}$ 

Sheet 13 of 17

FORM PTO-1	449, Adapted	LIST OF	INFORMATIO	Sheet 13 of 17						
	OCKET		SERIAL NO.	FILING DATE						
03757-02 APPLIC			09/287,377	April 7, 1999 GROUP						
	. D'Ama	to		1614						
			REFERENCES (Includ	ding Author, Title, Date, Pertinent Pages, Etc.)						
	МА	Nicolau, et al., "Thalidomide: Treatment of Severe Recurrent Aphthous Stomatitis in Patients with AIDS", DICP, Vol. 24, No. 11, pp. 1054-1056 (1990)								
M	МВ	Nielsen, et al., "Thalidomide Enhances Superoxide Anion Release from Human Polymorphonuclear and Leukocytes", Acta. Pathol. Microbiol. Immunol. Scand. [C], Vol. 94, No. 6, pp. 233-237 (1986)								
V	МС			ory Investigation A Hemangioendothelioma-Derived Cell Line: Its Use as Cell Biology", <i>Laboratory Investigation</i> , Vol. 63, No. 2, pp. 259-269						
	MD	Oikawa, T.		Novel Antibiotic is a Highly Powerful Angiogenesis Inhibitor", <i>Biochem.</i> No. 3, pp. 1070-1077 (1991)						
	ME	Olson, et al.,	"Thalidomide (N-phthal	oylglutamimide) in the Treatment of Advanced Cancer", o. 3, pp. 292-297 (1965)						
	MF			n Neonatologica", Ped. Med. Chir., Vol. 14, pp. 105-112 (1992)						
		Ostraat, et al	., "Thalidomide Prolong	s Graft Survival in Rat Cardiac Transplants", Transplant Proc.,						
	MG		. 6, pp. 2624-2625 (1992							
	мн		I., "A New Potent Angio . 163-168 (1991)	ogenesis Inhibitor, FR-118487", J. of Microbiol. and Biotechno., Vol.						
	MI			ncurrent Sessions", Pediatr. Dermatol, Vol. 9, No. 4, pp. 397-406 (1992)						
	МЈ	Angiogenesi	s and Antiangiogenic Ag	oratory Investigation A Simple, Quantitative Method for Assessing gents Using Reconstituted Basement Membrane, Heparin, and Fibroblast pation, Vol. 67, No. 4, pp. 519-528 (1992)						
	MK		al., "Thalidomide et colit	te ulcereuse dans la maladie de Behcet", Gastroenterol. Clin. Biol., Vol.						
	ML	Pearson, et a	d., "Treatment of Modera	ately Severe Erythema Nodosum Leprosum with Thalidomide – A br. Rev., Vol. 40, No. 2, pp. 111-116 (1969)						
	MM	Peyron, et a		Basis for the Treatment of Photodermatoses", Biochimie, Vol. 68,						
	MN	Pfordte, "Ûb		Serumproperdinsystems Durch Verschiedene Arzneimittel", (71)						
	МО		il., "Tumor Necrosis Fac natomical Rec., Vol. 245	etor Alpha (rhTNF) Fails to Stimulate Angiogenesis in the Rabbit 5, pp. 53-56 (1996)						
	MP	Powell, R.J.	et al., "Investigation and	Treatment of Orogenital Ulceration; studies on a Possible Mode of Dermatol., Vol. 113, Supp. 28, pp. 141-144 (1985)						
	MQ	Prigent, F. e 3007 (1983)		e Traitement par la Thalidomide", <i>La Presse Medicale</i> , Vol. 12, No. 47, p.						
	MR		G., "Thalidomide: An Ed 1-46. (Abstract Only) <b>19</b>	clectic Medication in Dermatology", Rev. Paul. Med., Vol. 107,						
	MS			Ilcer in Patient Infected with Human Immunodeficiency Virus: nide", J. Am. Acad. Dermatol, Vol. 23, No. 3, Pt. 1, pp. 523-525 (1990)						
	MT	Rainsford, K		Antirheumatic and Immunoregulatory Agents", Bailliere's Clinical						
	MU	Rajan, et al., "A Clinical Study of Thalidomide Comparing Pre-Treatment and Post-Treatment Reactional Episodes and Corticosteroid Requirements", Lepr. India, Vol. 55, No. 1, 111-116 (1983)								
	MV	Randall, T.,	"Investigational New Dr 263, No. 11, p. 1474 (1	ug (US) 'Orphan' Trials now Use Thalidomide from two Sources",						
	MW	Revuz, J., "	Actualite Du Thalidomid	le", Ann. Dermatol. Venereol., Vol. 117, pp. 313-321 (1990)						
	MX	Revuz, J. et		Thalidomide vs. Placebo in Severe Recurrent Aphthous Stomatitis", Arch.						
	MY ()		., "Role for Thalidomide	e in Primary Biliary Cirrhosis Treatment?", Gastroenterology, Vol. 105,						
EXAMINER	I MAL.	o Orner	- \	DATE CONSIDERED 197000						
EXAMIN	ER: Initial	if reference con	nsidered, whether or not cit	tation is in conformance with MPEP 609; Draw line through citation if not in						
conformanc	e and not c	onsidered. Incl	ude copy of this form with	n next communication to applicant.						

JAN 1-9 2000

(Use several sheets if necessary)

	(Use several sheets if necessary)						
ATTY.	DOCKE	r NO.	SERIAL NO.	FILING DATE			
03757-0 APPLIC			09/287,377	April 7, 1999 GROUP			
AFFLIC	ANI			GROOF			
Robert .	J. D'Am			1614			
	<del></del>			ding Author, Title, Date, Pertinent Pages, Etc.)			
- \\\	NA			Plasmin Enzyme System", Fibrinolysis, pp. 340-357 (2) 1447			
<del>                                      </del>	NB NC			e and Neoplasia", <i>Nature</i> , Vol. 200, pp. 1016-1017 (1963) ogeny of Thalidomide-Treated Mice", <i>British J. Cancer</i> , pp. 331-333,			
	INC	(1965)	Tumour-medence in Fi	ogeny of Thandonnide-Treated Wilce, British J. Cancer, pp. 331-333,			
V	ND			mori Sperimentali", Cancro, Vol. 20, pp. 39-55 (1967)			
	\			sum Associated with Behcet's Disease: Treatment with Thalidomide",			
<del>                                     </del>	NE			o. 5, Pt. 1, pp. 941-944 (1990) Esophageal Ulcer in AIDS (6)", New Engl. J. Med., Vol. 327, No. 3,			
	NF	pp. 208-209	(1992)				
	NG	Salven, P. et	al., "Serum Vascular E	ndothelial Growth Factor Is Often Elevated in Disseminated Cancer",			
			icer Research, Vol. 3, p				
	NH			nt with Recombinant Interferon Gamma Induces Erythema Nodosum Exp. Med., Vol. 175, No. 6, pp. 1729-1737 (1992)			
	NI			tively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated			
		Human Mor	nocytes", J. Exp. Med.,	Vol. 173, No. 3, pp. 699-703 (1991)			
	NJ			and its Management", Curr. Opin. Dent, Vol. 1, No. 6,			
$\vdash$	NK		(1991) (Abstract Only)	rosis Factor Production by Mononuclear Cells from Lepromatous			
	INK			with Erythema Nodosumleprosum", Clin. Immunol. Immunopathol.,			
		Vol. 67, No	. 3 I, pp. 199-203 (1993	3)			
	NL	Sato, K. et a	l., "Increased Concentra	tion of Vascular Endothelial Growth Factor/Vascular Permeability Factor			
			d of Enlarging and Recu , Vol. 82, No. 6, pp. 196	arrent Thyroid Nodules", Journal of Clinical Endocrinology and			
	NM			s and Angiogenesis Inhibitors in Paediatric Diseases", European J. of			
		Pediatric, V	ol. 151, pp. 472-476 (19	992)			
	NN			ovo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism			
	NO			amunol., Vol. 13, No. 6, pp. 553-562 (1981) Tectiveness in Erythema Nodosum Leprosum is Associated with a			
				pheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992)			
	NP	Shealy, Y.F	et al., "D-and L-Thalide	omide", Chemistry and Industry, pp. 1030-1031 (1965)			
				toxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29,			
	NQ	No. 10, p. 1		A Twenty-Five Year Perspective", Food Drug Cosmetic Law J., Vol. 41,			
	NR	pp. 458-466		A Twenty-Five Teal Ferspective, Food Drug Cosmette Law J., vol. 41,			
		Sheskin, J.,	"The Treatment of Lepra	a Reaction in Lepromatous Leprosy. Fifteen Years' Experience with			
	NS	Thalidomid	e", Int. J. Dermatol., Vo	ol. 19, No. 6, pp. 318-322 (1980)			
	NET			ents of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients			
	NT			ologica, Vol. 162, No. 2, pp. 86-90 (1981) d Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178,			
1 /	NU		60-368 (1991)	a radium Donataration, Diochem and Diophy. Res. Comm., 101. 170,			
		Sidky, Y. et	al., "Inhibition of Angio	ogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced			
H-	NV	Vascular Re	esponses", Canc. Res., V	/ol. 47, pp. 5155-5161 (1987)			
<del>  \</del>	NW NX			n", Persp. Biol. Med., pp. 617-637 (1980)  onship Between the Chemical Structure and Embryotoxic Activity of			
ν	1,47			ds", Chemical Structure and Embryopathy, pp. 194-209 1945			
EXAMINE	R	7		DATE CONSIDERED A			
EXAMIN		e Agner	seidered whether or not a	itation is in conformance with MPEP 609; Draw line through citation if not in			
				th next communication to applicant.			
	<del></del>						

conformance and not considered. Include copy of this form with next communication to applicant.

JAN 1 9 2000

### LIST OF INFORMATION DESCLOSED BY APPLICANT

(Use several sheets if necessary)

1			(Ose sev	erai sneets if necessary)				
ATTY.	Y. DOCKET NO. SERIAL NO.			FILING DATE				
03757-0	3757-0272 09/287,377			April_7, 1999				
APPLIC	CANT			GROUP				
L								
Robert	J. D'A			1614				
<u> </u>	10.1			ding Author, Title, Date, Pertinent Pages, Etc.)				
00	OA	Melanoma", 06745734)	Am. J. Pathol., Vol. 13	c Significance of Tumor Vascularity in Intermediate-Thickness Skin 13, pp. 419-423 (1988) (abstract from MEDLINE: Accession no.				
L Y	ОВ		arly Diagnosis and Trea 1, 172-178 (1995)	atment of Leprosy in the United States", American Family Physician,				
	OC		l., "Effect of Thalidomi 57-60 (1964)	de on Transplantable Mouse, Rat, and Hamster Tumors", GANN,				
	OD			ic Diseases in Japan", First Department of Internal Medicinie, University yushu, Japan, pp. 35-40 1443				
	OE			ma Nodosum Leprosum", Lancet, Vol. 2, No. 835, p. 966 (1973				
	OF			tion of Thalidomide as a Block of Functional Groups of Proteins in a Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978)				
	OG			omide and Cyclosporine for Cardiac Allograft Rejection. Comparison one and Cyclosporine", <i>Transplantation</i> , Vol. 49, No. 1, p. 20-25 (1990)				
	ОН		t al., "Vascular Endothe	elial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p.				
	OI		Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", <i>Nature</i> , Vol. 297, pp. 307-312 (1982)					
	OJ		Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", <i>The Lancet</i> , Vol. II, No. 8034, p. 405 (1977)					
	OK		"Thalidomide 20 Years On", <i>The Lancet</i> , Vol. II, No. 8245, pp. 510-511 (1981)					
	OL	"Thalidomid	e", The Merck Index, 1	1th ed., p. 1458 (1989)				
	OM		Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", <i>Lepr. India</i> , Vol. 52, No. 3, pp. 423-428 (1980)					
	ON	Thomas, et a	Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", <i>Indian J. Exp. Biol.</i> , Vol. 10, pp. 314-315 (1972)					
	00	Thomas, et a	Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", <i>Indian J. Exp. Biol.</i> , Vol. 10, pp. 316-317 (1972)					
	OP	Thomas, L.	Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993)					
	OQ	Torry, R. J.	Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992)					
	OR	Traldi, et al., Sintomatica	Traldi, et al., ""L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965)					
1_/	os	Trautman, J.	R., "Treatment of Han	sen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976)				
V	ОТ		ek, H., "Treatment of P	rurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5,				
EXAMINE	low	Me Some		DATE CONSIDERED				
				itation is in conformance with MPEP 609, Draw line through citation if not in the next communication to applicant.				
	$\vee$	V						

## JAN 1

### LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

			(Use seve	eral sheets if necessary)			
ATTY. D	OCKET	NO.	SERIAL NO.	FILING DATE			
03757-02	272		09/287,377	April_7, 1999			
APPLICA				GROUP			
	<b>D</b>			1444			
Robert J.	. D'Ama		DEEEDENCES (Ll.	1614			
<del>                                     </del>	PA			ding Author, Title, Date, Pertinent Pages, Etc.) Actiunea Talidomidei Asupra Celulelor Cultivate in Vitro", Cerc.			
W/k	PA	Fiziol., Vol.	13, No. 4, pp. 293-300	(1968)			
	PB			Antiangiogenic Therapy with Thalidomide and Sulindac Inhibits Tumor, Vol. 79, No. 1, pp. 114-118 (1999)			
	PC	Vicente, T. 6	et al., "In Vitro Activity	of Thalidomide Against Mycobacterium avium Complex", Archives of			
<del>                                      </del>	PD		dicine, Vol. 153, p.334 (	Γhalidomide and its Metabolites on the Chick Embryo Blood Cells",			
	<sup>PD</sup>		atina, Vol. 6, pp. 217-2				
	PE			Thalidomide", The Lancet, pp. 725 (1963)			
	PF			Thalidomide?", The Lancet, Vol. I, No. 7444, pp. 981-982 (1966)			
	PG	Vogelsang,		e for the Treatment of Chronic Graft-Versus-Host Disease", New England			
	PH			nic Graft-v-Host Disease in a Rat Model", <i>Blood</i> , Vol. 74, No. 1,			
		No. 1, pp. 5	07-511 (1989)				
	PI		et al., "Thalidomide Indu 1, Pt. 3, pp. 2658-266	ction of Bone Marrow Transplantation Tolerance", <i>Transplant Proc.</i> , 1 (1987)			
	PJ			evention of Acute Graft-versus-Host Disease with Thalidomide in a Rat			
		Model", Tra	nsplantation, Vol. 41, N	No. 5, pp. 644-647 (1986)			
	PK	Vogt, B. et al., "Inhibition of Angiogenesis in Kaposi's Sarcoma by Captopril", <i>The Lancet</i> , Vol. 349, p. 1148 (1997)					
	PL	Waters, M.F 792 (1979)	et al., "Treatment of U	Ilcerative Colitis with Thalidomide", Brit. Med. J., Vol. 1, No. 6166, pp.			
	PM		"Use of Thalidomide in	Leprosy", BMJ, Vol. 303, No. 6800, p. 470 (1991)			
				lled Double Blind Trial of Thalidomide in Severe Erythema Nodosum			
	PN	Leprosum",	Lepro. Rev., Vol. 42, N	Io. 1, pp. 26-42 (1971)			
	PO		et al., "Tumor Angiogen of Med., Vol. 324, No. 1	esis and Metastasis-Correlation in Invasive Breast Carcinoma", <i>The New</i> , pp. 1-8 (1991)			
	PP	Weidner, N.	et al., "Tumor Angioge	nesis Correlates with Metastasis in Invasive Prostate Cancer", Am. J. of			
			. 143, No. 2, pp. 401-40				
	PQ			nesis: A New Significant and Independent Prognostic Indicator in Early- Canc. Inst., Vol. 84, No. 24, 1875-1887 (1992)			
	PR	Wesolowski	, et al., "Effect of Light	on a Murine Model of Retinopathy of Prematurity", Invest. Opthamol. &			
	PS	Visual Science, Vol. 33, No. 4, p. 1281 (Abstract only) 1944 White, C. W. et al., "Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2a", The					
<del></del>	D.T.			(o. 18, pp. 1197-1200 (1989)			
	PT	Williams, K 295 (1990)	. M., "Enantiomers in A	arthritic Disorders", Pharmacol. & Therapeutics, Vol. 46, No. 2, pp. 273-			
	PU		al., "Thalidomide Hype	ersensitivity in AIDS", Lancet, Vol. 337, pp. 436-437 (1991)			
$\overline{}$	P.V		n, et al., "Thalidomide T	reatment of Prurigo Nodularis", Acta. Derm. Venereol., Vol. 64, No. 5,			
EXAMINER		C.	(2,01)	DATE CONSIDERED			
	MUTUL	e Stones		DATE CONSIDERED			
	R: Inilia	l if reference cor		itation is in conformance with MPEP 609; Draw line through citation if not in			
conformance	e and not	considered. Incl	ude copy of this form with	h next communication to applicant.			

LIST	<b>OF</b>	INFO	RMA	ATTQN	DISCI	OSED	BY	<b>APPL</b>	<b>ICANT</b>
------	-----------	------	-----	-------	-------	------	----	-------------	--------------

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE	
03757-0272	09/287,377	April 7, 1999	
APPLICANT		GROUP	
Robert L. D'Amato		1614	

Robert J. D'Amat	1614
	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
n d	Wood, et al., "The Potential use of Thalidomide in the Therapy of Graft-versus-Host Disease - A Review of
W/V   QA	Clinical and Laboratory Information", Leuk. Res., Vol. 14, No. 5, pp. 395-399 (1990)
V QB	Woodyatt, P.B., "Thalidomide", The Lancet, p. 750. (1962)
QC	Wulff, et al., "Development of Polyneuropathy During Thalidomide Therapy", Br. J. Dermatol., Vol. 112,
	No. 4, pp. 475-480 (1985)
QD	Yazici, et al., "Practical Treatment Recommendations for Pharmacotherapy of Behcet's Syndrome", Drugs,
	Vol. 42, No. 5, pp. 796-804 (1991)
QE	Yoshimura, T. et al., "Cloning, Sequencing, and Expression of Human Macrophage Stimulating Protein
	(MSP, MST1) Confirms MSP as a Member of the Family of Kringle Proteins and Locates the MSP Gene on
	Chromosome 3", The J. of Biol. Chem., Vol. 268, No. 21, pp. 15461-15468 (1993)
QF	Youle, et al., "Treatment of Resistant Aphthous Ulceration with Thalidomide in Patients Positive for HIV
	Antibody", BMJ, Vol. 298, No. 6671, p. 432 (1989)
QG	Youle, et al., "Thalidomide in Hyperalgic Pharyngeal Ulceration of AIDS", Lancet, Vol. 335, No. 8705,
	p. 1591 (1990)
QH	Yue, t. et al., "2-Methoxyestradiol, an Endogenous Estrogen Metabolite, Induces Apoptosis in Endothelial
1 1 1 1 1	Cells and Inhibits Angiogenesis: Possible Role for Stress-Activated Protein Kinase Signaling Pathway and Fas
	Expression", Molecular Pharmacology, Vol. 51, pp. 951-962 (1997)
QI	Ziche, M. et al., "Nitric Oxide Synthase Lies Downstream from Vascular Endothelial Growth Factor-induced
1 1, 1 1 1	but Not Basic Fibroblast Growth Factor-Induced Angiogenesis", J. Clin. Invest., Vol. 99, No. 11, pp. 2625-
	2634 (1997)
/4/  QJ	Zwart, D., "Treatment of Grade II Astrocytoma with Thalidomide", ArzneimForsch., Vol. 16, No. 12, pp.
	1688-1689 (1966)
EXAMINER ()	DATE CONSIDERED